320 related articles for article (PubMed ID: 26004003)
1. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
[TBL] [Abstract][Full Text] [Related]
2. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats.
Wang JL; Liu YL; Li Y; Dai WB; Guo ZM; Wang ZH; Zhang Q
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):7348-57. PubMed ID: 22977140
[TBL] [Abstract][Full Text] [Related]
3. Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.
Patel K; Doddapaneni R; Sekar V; Chowdhury N; Singh M
Mol Pharm; 2016 Jun; 13(6):2049-58. PubMed ID: 27070720
[TBL] [Abstract][Full Text] [Related]
4. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
[TBL] [Abstract][Full Text] [Related]
5. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
6. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.
Wang Z; Yu Y; Dai W; Lu J; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2012 Nov; 33(33):8451-60. PubMed ID: 22940213
[TBL] [Abstract][Full Text] [Related]
7. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
[TBL] [Abstract][Full Text] [Related]
8. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells.
Dai W; Yang T; Wang X; Wang J; Zhang X; Zhang Q
J Drug Target; 2010 May; 18(4):254-63. PubMed ID: 19824864
[TBL] [Abstract][Full Text] [Related]
9. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
10. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
[TBL] [Abstract][Full Text] [Related]
11. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
12. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
Wang Z; Yu Y; Dai W; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(3):756-64. PubMed ID: 23117217
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
14. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
[TBL] [Abstract][Full Text] [Related]
15. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
16. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
17. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy.
Cai D; Gao W; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2014 Feb; 35(7):2283-94. PubMed ID: 24360410
[TBL] [Abstract][Full Text] [Related]
18. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
19. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
20. Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
Yao J; Feng J; Gao X; Wei D; Kang T; Zhu Q; Jiang T; Wei X; Chen J
Biomaterials; 2017 Jan; 113():1-17. PubMed ID: 27794222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
